Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Esomeprazole

From Pharmacopedia
Revision as of 03:51, 23 May 2026 by MDElliottMD (talk | contribs) (parser-claude batch MedTemplate pre-fill, Top 300 #147)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Esomeprazole
Nexium, Nexium 24HR (OTC)

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Common uses
GERD0, Erosive esophagitis (healing and maintenance)0, H. pylori eradication (combination)0, Zollinger-Ellison syndrome0, NSAID-associated ulcer prophylaxis0
Pharmacy
Starting dose
20-40 mg PO once daily, 30-60 minutes before breakfast
Preparations
20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV
US FDA Max
40 mg/d typical; up to 240 mg/d for Zollinger-Ellison
Pharmacology
Routes
Oral, IV
Onset
Acid suppression within hours; full effect after 3-5 days of dosing
Duration
24-72 hours per dose (irreversible enzyme binding)
Half-life
~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover[2]
Bioavailability
~64-90% (oral; increases at higher doses and with multi-day dosing)[2]
Pregnancy
Widely used in obstetric reflux; reassuring data.[citation needed]
Legal status
OTC (20 mg, 14-day course) and Rx-only (higher and longer durations) in US
Purported mechanism
Esomeprazole is the S-enantiomer of omeprazole; chiral separation reduces inter-individual variability driven by CYP2C19-mediated R-enantiomer clearance, yielding more consistent acid suppression than racemic omeprazole, particularly in CYP2C19 extensive metabolizers.0 Like omeprazole, it is an acid-activated prodrug that covalently and irreversibly binds the H+/K+ ATPase. CYP2C19 PGx remains clinically relevant for both[1].

References

  1. CPIC Guideline for CYP2C19 and Proton Pump Inhibitors, 2020. https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/
  2. 2.0 2.1 FDA Prescribing Information, Nexium (esomeprazole magnesium), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021153s050,021957s017,022101s014,021689s029,022101s009lbl.pdf